Medicare GLP-1 Bridge Program 2026: Eligibility, Costs & How to Enroll

Last updated: May 28, 2026

The Medicare GLP-1 Bridge Program launches July 1, 2026 and offers eligible Medicare beneficiaries access to specific GLP-1 weight-loss medications at a flat $50/month copay. It's a short-term fix — not a new permanent benefit — and the rules around eligibility, covered medications, and the post-2027 future have caveats most consumer coverage glosses over. This guide lays out the full picture honestly: what the program is, who qualifies, what it actually costs, how to enroll, and what to plan for if it ends.

What Is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge is a temporary payment demonstration administered by the Centers for Medicare & Medicaid Services (CMS). It was announced December 23, 2025 and launches July 1, 2026. The Bridge allows eligible Medicare beneficiaries to access certain GLP-1 weight-loss medications for a flat $50/month copay, processed through their existing Part D or Medicare Advantage drug plan.

Three things to be clear about up front:

• It is not a new permanent Medicare benefit. It is a time-limited demonstration scheduled to run from July 1, 2026 through December 31, 2027.
• It is not automatic. Eligible beneficiaries must meet specific clinical and plan-enrollment criteria, and your doctor must submit a prior authorization request before you can access the $50 copay.
• It does not change Medicare's general policy that GLP-1s prescribed for weight loss alone are not covered under standard Part D. The Bridge sits on top of that policy as a separate, time-limited program.

The Bridge was originally designed to lead into a larger CMMI innovation model — the BALANCE Model — that would have created permanent Part D coverage of GLP-1 obesity medications. As of April 21, 2026, the Part D portion of BALANCE has been indefinitely delayed. We cover what that means for the post-2027 future further down.

Which Medications Are Covered?

The single biggest source of confusion about the Bridge Program is which GLP-1 medications it actually covers. The program covers only GLP-1s that are FDA-approved for weight loss or obesity. GLP-1s approved for type 2 diabetes are excluded — even though they contain the same active ingredients as their weight-loss counterparts.

Covered Under the Bridge

• Wegovy (semaglutide) — all formulations, including the new oral tablet.
• Zepbound (tirzepatide) — KwikPen formulation only. The single-dose vial and single-dose pen formulations of Zepbound are not covered under the Bridge.
• Foundayo (orforglipron) — all formulations.

Not Covered Under the Bridge

• Ozempic (semaglutide) — FDA-approved for type 2 diabetes, not weight loss. Remains covered under standard Part D for diabetes patients on its existing terms; the Bridge does not change that.
• Mounjaro (tirzepatide) — FDA-approved for type 2 diabetes, not weight loss. Same as Ozempic above.

Quick Comparison: What's Covered and What's Not

If you're taking Ozempic or Mounjaro for diabetes, your current Part D coverage isn't affected — the Bridge simply doesn't apply to those medications. If your goal is weight loss specifically, ask your doctor about switching to Wegovy, Zepbound (KwikPen), or Foundayo, all of which can run through the Bridge if you qualify.

Eligibility Criteria

The Bridge has two eligibility layers: which Medicare drug plan you're enrolled in, and the clinical criteria at the time you started or were prescribed GLP-1 therapy.

Plan Eligibility

You must be enrolled in one of the following plan types:

• Standalone Medicare Part D plan (PDP)
• Medicare Advantage plan with drug coverage (MA-PD)
• Special Needs Plans (SNP)
• Employer Group Waiver Plans (EGWP)
• Limited Income NET (LI NET)

If you have Original Medicare without any prescription drug plan, the Bridge will not apply to you until you enroll in one of the plans above.

Clinical Eligibility

Clinical eligibility is based on your BMI and health status at the time GLP-1 therapy was initiated — not your current BMI after any treatment-related weight loss. You must meet ONE of these three thresholds:

1. BMI 35 or higher — no additional health conditions required.
2. BMI 30 to 34.9 — plus at least one of: heart failure, uncontrolled hypertension, or chronic kidney disease stage 3a or higher.
3. BMI 27 to 29.9 — plus at least one of: pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.

If you're not sure where you fall, our free Medicare GLP-1 Bridge eligibility checker walks you through these criteria in about a minute. The checker doesn't replace your doctor's evaluation, but it can tell you whether it's worth bringing the program up at your next appointment.

What Does It Cost?

The headline number is $50/month flat copay for any covered medication on any covered dose, paid through your existing pharmacy benefit. But there are two important caveats that most consumer-facing coverage misses:

The $50 copay does NOT count toward your Part D deductible or out-of-pocket maximum

Under normal Part D rules, the amount you pay for covered drugs counts toward your annual deductible and your annual out-of-pocket maximum (which triggers catastrophic coverage). Bridge prescriptions are processed outside that accumulation. Your $50/month Bridge copays do not reduce what you owe on your other Part D medications.

Low-Income Subsidy (Extra Help) recipients may pay MORE under the Bridge

If you receive Medicare's Low-Income Subsidy — the program also known as "Extra Help" — the LIS cost-sharing schedule (which typically reduces brand-name copays to a few dollars) does not apply to Bridge prescriptions. The $50 flat copay applies regardless of LIS status.

This creates a counterintuitive situation: some Extra Help recipients whose plans already cover Wegovy or Zepbound under standard Part D may pay less under their existing coverage than they would under the Bridge. If you receive Extra Help, talk to your Part D plan before opting into the Bridge — they can tell you what your current copay would be on the same medication.

How to Enroll

There is no separate enrollment process for the Bridge. Access is built into your existing Part D or Medicare Advantage drug plan. The steps are:

1. Talk to your doctor about whether you meet the clinical criteria above. Bring documentation of any qualifying conditions (heart failure, prior stroke, etc.) if applicable.
2. Your provider submits a prior authorization request to a central CMS processor operated by Humana. This is different from typical Part D prior authorizations, which go to your individual plan. The Bridge uses a single CMS-contracted processor across all Medicare drug plans for consistency.
3. If approved, your pharmacy fills the prescription at the $50/month copay. The pharmacy bills under your existing plan; you pay $50 at the counter (or whatever your plan's mail-order arrangement is).

CMS released full prior authorization details in its May 2026 FAQ update. The processor was selected through a competitive bid; CMS chose Humana to operate it but Bridge eligibility is not limited to Humana plan members.

What Happens After December 2027?

This is where you have to plan for uncertainty, because the situation is unsettled and the consumer-facing communications have not been clear about it.

The Bridge was originally designed as the on-ramp to a permanent program: the BALANCE Model, a 5-year CMMI innovation model that would have created permanent Part D coverage of GLP-1 obesity medications using a negotiated $245 net drug price. The plan was for beneficiaries to transition from the Bridge into BALANCE coverage with continuity.

On April 21, 2026, CMS indefinitely delayed the Part D portion of the BALANCE Model. The reason given: Part D plans found the economics unfavorable. The negotiated $245 net price still meant that increased GLP-1 utilization would cost plans more than they would save on the negotiated discount, and plans were unwilling to participate at scale.

As of late May 2026:

• There is no confirmed pathway to permanent Medicare coverage of GLP-1 obesity medications after the Bridge expires December 31, 2027.
• Congress could create permanent coverage through legislation, but no bill is currently pending.
• CMS could extend the Bridge, restructure BALANCE, or announce a new model — but has not signaled any of these as imminent.

The honest framing if you're considering starting a GLP-1 through the Bridge: plan for the possibility that coverage may not continue past 2027. Some people will see their costs return to either retail Part D pricing (which can be over $1,000/month for Wegovy or Zepbound without a copay card) or self-pay prices through alternative pathways. If continuity of treatment is critical to your situation, it's worth thinking through the post-2027 fallback before starting.

Bridge Program vs. Current Self-Pay Options

The Bridge is the cheapest path for people who qualify — $50/month is below virtually every self-pay option for brand-name Wegovy or Zepbound. But it has constraints that don't apply to self-pay:

For people who don't qualify for the Bridge, or who want to start treatment before July 1, 2026, telehealth self-pay is the realistic alternative. Our GLP-1 cost comparison tool shows current real prices across 10+ telehealth providers — sorted by total monthly cost, with the full fee breakdown for each provider where it's publicly available. Before signing up with any telehealth provider, work through our provider legitimacy checklist — a six-step verification that takes a few minutes and protects you from scam sellers that have become increasingly common in the GLP-1 market.

Next Steps

• Check your eligibility — five questions, instant result, no email required.
• Compare current self-pay GLP-1 prices in case you don't qualify or want to start before July 2026.
• Talk to your doctor at your next visit. If you think you meet the clinical criteria, ask whether they'll be prepared to submit the Bridge prior authorization when it opens.

Sources & References

• CMS — Medicare GLP-1 Bridge program overview
• Medicare.gov (1-800-MEDICARE for personalized guidance)
• Kaiser Family Foundation — Medicare coverage analysis

Related Reading

• Medicare GLP-1 Coverage in 2026 — the broader picture beyond just the Bridge
• Earlier Medicare Bridge primer (April 2026 reporting)
• Oral GLP-1 cost comparison: Wegovy pill vs Foundayo — covered under the Bridge
• State-by-state Medicaid GLP-1 coverage
• Cheapest Wegovy options without insurance